Archive for the ‘clinical study retractions’ Category
Two authors of a 2012 paper sponsored by a company that made grand claims about green coffee bean extract’s abilities to help people lose weight have retracted it. The study was cited by The Dr. Oz Show, and last month it cost the company a $3.5 million settlement with the Feds.
Here’s the notice for “Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects,” a paper originally published in Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy: Read the rest of this entry »
Journal expresses concerns over “possible data irregularities” in paper from Army medical center docs
The Journal of the American Academy of Dermatology has issued an expression of concern about a 2012 article reporting the experience of military burn unit treating a rare ailment called toxic epidermal necrolysis.
According to the notice, which is behind a paywall (for shame!), the paper appears to have overstated the number of cases the hospital itself has treated of the life-threatening condition: Read the rest of this entry »
A cancer paper was retracted on September 17 for a double publication. According to the notice in which the authors admit to duplicating the “opening to the readers,” which we assume is the introduction, there was no need to cite the article “because it had not yet been printed at that time.”
The retraction notice indicates that the patients never consented, there was no ethical review, and the university supposedly overseeing the study had no knowledge of it:
We’ve written before about how common cell line mix ups are in cancer research; according to a 2012 Wall Street Journal article (paywalled), between a fifth and a third of cancer cell lines tested by suspicious researchers turned out to be misidentified.
Obviously, mistakenly studying the wrong kind of cancer is a waste of precious resources, both time and money. And it’s clear the problem hasn’t gone away. PLoS ONE just retracted a cancer paper originally published in December 2012 for studying two cell lines that had been contaminated by other cell types.
Here’s the notice in Cancer Immunology, Immunotherapy for “Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF:” Read the rest of this entry »
Phyllis Wise, the chancellor of the University of Illinois and an obstetrics researcher, has called for a massive correction of a 2006 paper in Neuroscience for work she appears to have tried to pass off as having been previously unpublished — but which wasn’t.
The article, “Estrogen therapy: Does it help or hurt the adult and aging brain? Insights derived from animal models,” has been cited 47 times, according to Thomson Scientific’s Web of Knowledge.